Changwu Ma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Changwu Ma has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Binghe Xu
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
1 shared publication - Chunhong Hu
Department of Oncology, the Second Xiangya Hospital of Central South University
1 shared publication Fan Wu
Department of Biochemistry and Molecular Biology, State Key Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100005, China
1 shared publicationFei Miao
Department of Biochemistry and Molecular Biology, State Key Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100005, China
1 shared publication- Hongge Ju
Department of Pathology, Baotou Medical College, Baotou, 014040, China
1 shared publication - Jie Li
Department of Radiation Oncology, Shanxi Province Cancer Hospital, Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences, Cancer Hospital Affiliated to Shanxi Medical University, Shanxi, China
1 shared publication
Latest Publications
- Open Access
- 2 April 2019
- Published by American Association for the Advancement of Science (AAAS) in Cancer Communications
- Vol. 39 (1) , 16
Irinotecan plus S‐1 versus S‐1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open‐labeled phase 3 trial
Background: The benefit of systemic treatments in esophageal squamous cell carcinoma (ESCC) which has progressed after chemotherapy is still uncertain and optimal regimens based on randomized trials have not yet been established. We aimed to compare the efficacy of irinotecan plus S‐1 with S‐1 monotherapy in recurrent or metastatic ESCC patients who had resistance to platinum‐ or taxane‐based chemotherapy. Methods: We conducted a prospective randomized, multicenter, open‐label, phase 3 trial in 15 centers across China. Eligible patients were adults with histologically confirmed recurrent or metastatic ESCC, and were randomly assigned (ratio, 1:1) to receive either irinotecan plus S‐1 (intravenous infusion of irinotecan [160 mg/m 2 ] on day 1 and oral S‐1 [80–120 mg] on days 1–10, repeated every 14 days) or oral S‐1 monotherapy (80–120 mg/day on days 1–14, repeated every 21 days) using a central computerized minimization procedure. The primary endpoint was progression‐free survival (PFS). Results: Between December 23, 2014 and July 25, 2016, we screened 148 patients and randomly assigned 123 patients to receive either irinotecan plus S‐1 regimen ( n = 61) or S‐1 monotherapy ( n = 62). After a median follow‐up of 29.2 months (95% confidence interval [CI] 17.5–40.9 months), the median PFS was significantly longer in the irinotecan plus S‐1 group than in the S‐1 monotherapy group (3.8 months [95% CI 2.9–4.3 months] vs. 1.7 months [95% CI 1.4–2.7 months], hazard ratio = 0.58, 95% CI 0.38–0.86, P = 0.006). The objective response rates were 24.6% in the irinotecan plus S‐1 group and 9.7% in the S‐1 monotherapy group ( P = 0.002). The patients in the irinotecan plus S‐1 group presented with increased rates of grade 3–4 leukopenia (16.4% vs. 0%), neutropenia (14.8% vs. 1.6%), and nausea (4.9% vs. 0%). No significant difference in grade 3–4 diarrhea and no treatment‐related deaths were observed in both groups. Conclusions: The combination of irinotecan with S‐1 was similarly tolerable but significantly prolonged PFS compared to S‐1 monotherapy as a second‐ or third‐line treatment in patients with recurrent or metastatic ESCC. Clinical Trial Registration NCT02319187. Registered on December 9, 2014
- 2 April 2019
- Published by American Association for the Advancement of Science (AAAS) in Cancer Communications
- Vol. 39 (1) , 16
Open AccessIrinotecan plus S‐1 versus S‐1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open‐labeled phase 3 trial
Background: The benefit of systemic treatments in esophageal squamous cell carcinoma (ESCC) which has progressed after chemotherapy is still uncertain and optimal regimens based on randomized trials have not yet been established. We aimed to compare the efficacy of irinotecan plus S‐1 with S‐1 monotherapy in recurrent or metastatic ESCC patients who had resistance to platinum‐ or taxane‐based chemotherapy. Methods: We conducted a prospective randomized, multicenter, open‐label, phase 3 trial in 15 centers across China. Eligible patients were adults with histologically confirmed recurrent or metastatic ESCC, and were randomly assigned (ratio, 1:1) to receive either irinotecan plus S‐1 (intravenous infusion of irinotecan [160 mg/m 2 ] on day 1 and oral S‐1 [80–120 mg] on days 1–10, repeated every 14 days) or oral S‐1 monotherapy (80–120 mg/day on days 1–14, repeated every 21 days) using a central computerized minimization procedure. The primary endpoint was progression‐free survival (PFS). Results: Between December 23, 2014 and July 25, 2016, we screened 148 patients and randomly assigned 123 patients to receive either irinotecan plus S‐1 regimen ( n = 61) or S‐1 monotherapy ( n = 62). After a median follow‐up of 29.2 months (95% confidence interval [CI] 17.5–40.9 months), the median PFS was significantly longer in the irinotecan plus S‐1 group than in the S‐1 monotherapy group (3.8 months [95% CI 2.9–4.3 months] vs. 1.7 months [95% CI 1.4–2.7 months], hazard ratio = 0.58, 95% CI 0.38–0.86, P = 0.006). The objective response rates were 24.6% in the irinotecan plus S‐1 group and 9.7% in the S‐1 monotherapy group ( P = 0.002). The patients in the irinotecan plus S‐1 group presented with increased rates of grade 3–4 leukopenia (16.4% vs. 0%), neutropenia (14.8% vs. 1.6%), and nausea (4.9% vs. 0%). No significant difference in grade 3–4 diarrhea and no treatment‐related deaths were observed in both groups. Conclusions: The combination of irinotecan with S‐1 was similarly tolerable but significantly prolonged PFS compared to S‐1 monotherapy as a second‐ or third‐line treatment in patients with recurrent or metastatic ESCC. Clinical Trial Registration NCT02319187. Registered on December 9, 2014
- Open Access
- 25 February 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (15) , 25251-25260
RHBDD1 upregulates EGFR via the AP-1 pathway in colorectal cancer
RHBDD1 upregulates EGFR via the AP-1 pathway in colorectal cancer
- 25 February 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (15) , 25251-25260
Open AccessRHBDD1 upregulates EGFR via the AP-1 pathway in colorectal cancer
RHBDD1 upregulates EGFR via the AP-1 pathway in colorectal cancer